← All trials
NCT05471544
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 18, 2022
- Primary completion
- Dec 15, 2022
- Completion date
- Mar 1, 2023
- First posted
- Jul 25, 2022
- Last posted
- Sep 22, 2022
- Enrollment
- 3575
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Malaria ConsortiumLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.